Skip to main content

Remote Job Finders (RJF)

After 2 patient deaths and cell therapy durability concerns, Artiva cuts 94% of workforce

Artiva Biotherapeutics, which had been evaluating cell therapy AlloNK for the treatment of rheumatoid arthritis and other autoimmune diseases, is exploring strategic options that could include dissolution and liquidation.

Biotech IPOs raise $7.5B as sector’s performance rally flattens

While biopharma financing exit activity has remained strong through the third quarter, public-market performance for the same period was muted, with most of the yearly gains for the U.S. biotech-specific index largely driven by the first half of 2026.

ESMO 2026: Tango trips on sinking response rates in pancreatic cancer but will move to Phase 3

A combination of Tango Therapeutics’ vopimetostat and Revolution Medicines’ recently approved Rasonque led to a response rate of 82% in an ongoing Phase 1/2 trial—a drop from 92% that was reported in June in fewer patients.

Roche flags ‘final opportunity’ for Germany to reestablish as a reliable investment location

Following the withdrawal of billions of dollars in investments from Boehringer Ingelheim and Eli Lilly, German lawmakers have proposed a clause to the country’s healthcare reforms set to take effect Jan. 1.
Scroll to top